Novartis | NOVN - Чистый доход





Чистый доход Изменить Дата
AbbVie USD 3.61B 2.92B 2026-06
Alcon AG USD 189M 28M 2026-03
Almirall EUR 19.58M 7M 2025-12
Amgen USD 2.38B 556M 2026-06
AstraZeneca USD 2.51B 573M 2026-06
Autolus Therapeutics Ltd USD -71.6M 18.73M 2026-03
Bayer EUR 219M 2.54B 2026-06
Biogen USD 97.5M 222M 2026-06
Bristol-Myers Squibb USD 3.32B 640M 2026-06
Eli Lilly USD 7.1B 301M 2026-06
Fresenius EUR 382M 53M 2026-06
Fresenius Medical Care EUR 218.38M 100.38M 2026-06
Genmab DKK 303M 250M 2026-06
Gilead Sciences USD -10.5B 12.52B 2026-06
GlaxoSmithKline GBP 435M 1.3B 2026-06
GRIFOLS EUR 154M 81M 2026-06
Hikma Pharmaceutical USD 164M 45M 2025-12
J&J USD 5.53B 299M 2026-06
Lakefront Biotherapeutics EUR 2.11M 12.38M 2026-06
Lonza CHF 426M 119M 2025-06
Merck EUR 490M 169M 2026-06
Merck USD -1.34B 2.9B 2026-06
Novartis USD 3.26B 108M 2026-06
Novartis USD 3.16B 747M 2026-03
Novo Nordisk DKK 20.99B 5.9B 2026-06
Orion EUR 140.2M 49.8M 2026-06
Pfizer USD -248M 2.94B 2026-06
Philips EUR 384M 233M 2026-06
Recordati EUR 116.61M 36.45M 2026-06
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Roche Holding CHF 6.87B 1.4B 2026-06
Sanofi EUR 343M 1.27B 2026-06
UCB EUR 1.08B 608M 2025-12